Research programme: eye disorder therapeutics - Qurgen
Latest Information Update: 06 Sep 2023
At a glance
- Originator Qurgen
- Class Eye disorder therapies; Proteins
- Mechanism of Action Cell differentiation modulators; Cell differentiation stimulants; Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders; Glaucoma
Most Recent Events
- 27 Aug 2023 Qurgen has patent protection and patents pending, regarding "Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming" in various countries
- 24 Aug 2023 Preclinical trials in Eye disorders in China (Parenteral) (Qurgen pipeline, August 2023)
- 24 Aug 2023 Preclinical trials in Glaucoma in China (Parenteral) (Qurgen pipeline, August 2023)